로딩 중…
지수 로딩 중…
테라젠이텍스
066700· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,185-5.62%
2026-06-19
Price Chart
테라젠이텍스-27.65%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 81.18B KRW |
| Revenue | 272.93B KRW |
| Net Income | 9.93B KRW |
| Total Assets | 253.33B KRW |
| Net Assets | 152.04B KRW |
| Employees | 214 |
| Value | |
| P/E | 8.17x |
| P/B | 0.53x |
| P/S | 0.30x |
| EV/EBITDA | 74.31x |
| FCF Yield | 10.34% |
| Profitability | |
| ROE | 6.53% |
| ROA | 3.92% |
| Op. Margin | 0.62% |
| Revenue Growth | 1.99% |
| Financial Health | |
| Debt Ratio | 166.62% |
| Total Debt | 81.49B KRW |
| FCF | 8.40B KRW |
| Cash | 37.87B KRW |
| Current Ratio | 1.87x |
| Net Debt/EBITDA | 25.97x |
| Performance | |
| 1Y Return | -27.65% |
| 1M Return | -18.62% |
| From 52W High | -37.03% |
| 1Y MDD | -34.09% |
| Trading | |
| Volume | 121,679 shares |
| Foreign Own. | 2.33% |
| Per Share | |
| EPS | 262 KRW |
| BPS | 3,590 KRW |
Company Info
Theragen Etex, established in 1990 and listed on KOSDAQ in 2004, adopted its current name after merging with Etex Pharmaceutical in 2010. The company primarily manufactures and sells specialized and general medicines and provides genome sequencing services, with Leadfarm, Theragen Healthcare, and Theragen Bio as subsidiaries. Theragen Etex focuses on new drug R&D, DNA sequencing, and RNA variant genome analysis to address future medical changes, and is pursuing global market expansion through its Chinese local subsidiary. It is headquartered in Ansan-si, Gyeonggi-do.